CYTOSORBENTS CORPORATION

Analyst Reco. Cytosorbents Corporation

Equities

CTSO

US23283X2062

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
0.88 ^USD	+7.40%		+7.45%	-20.72%

03-15	Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-14	Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50	12-29	MT
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating	12-28	MT
US STOCKS -Wall Street edges higher as year end approaches, rate cuts in focus	12-28	RE
B. Riley Resumes Cytosorbents at Buy With $4 PT; Notes CytoSorb's Growth Potential, Risk-Adjusted Revenue Contribution of DrugSorb-ATR in US	07/09/23	MT
HC Wainwright Adjusts Price Target on Cytosorbents to $5.50 From $9, Maintains Buy Rating	04/11/22	MT
B. Riley Trims Cytosorbents' Price Target to $6 from $7, Lowers Revenue Estimates Despite Confidence for Mid-Term; Keeps Buy Rating	04/05/22	MT
HC Wainwright Adjusts Cytosorbents' Price Target to $9 from $13, Keeps Buy Rating	04/05/22	MT
B. Riley Lowers Cytosorbents' Price Target to $7 from $10, Notes Continued H1 Headwinds, Lowers Revenue Estimate for 2022; Keeps Buy Rating	10/03/22	MT
CYTOSORBENTS : B. Riley Resumes Cytosorbents at Buy with $10 PT, Says Headwinds Represent Buying Opportunity	14/10/21	MT
CYTOSORBENTS : B. Riley Adjusts Cytosorbents' Price Target to $17 From $16, Keeps Buy Rating	04/01/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer